Editor's Note :

Editor's Note :

We are expecting one or more decisions in argued cases tomorrow at 10 a.m. We will be live-blogging the opinion(s) as they are released. However, there is no live blog of tomorrow’s oral argument in King v. Burwell. We will have coverage of that argument as soon as possible after it is finished; the transcript should be available tomorrow afternoon, and the audio will be available on Friday.
Wednesday's live blog will be available here.

SigmaPharm, Inc. v. Mutual Pharmaceutical Co., Inc.

Petition for certiorari denied on October 1, 2012
Docket No. Op. Below Argument Opinion Vote Author Term
11-1275 3d Cir. N/A N/A N/A N/A OT 2012

Issue: Whether the Third Circuit has erred in restricting the availability of Section 4 of the Clayton Act, 15 U.S.C. § 15(a) -- which grants a private right of action for treble damages to “any person who shall be injured in his business or property by reason of anything forbidden in the antitrust laws” -- with a general rule that “[a]s a general matter, the class of plaintiffs capable of satisfying the antitrust-injury requirement is limited to consumers and competitors in the restrained market and to those whose injuries are the means by which the defendants seek to achieve their anticompetitive ends.”

SCOTUSblog Coverage

Briefs and Documents

Certiorari-stage documents

 
Share:
Term Snapshot
Awards